Anika Therapeutics Inc (NASDAQ:ANIK): Positive Stock Sentiment

Anika Therapeutics, Inc. (NASDAQ:ANIK) Logo

Sentiment for Anika Therapeutics Inc (NASDAQ:ANIK)

Anika Therapeutics Inc (NASDAQ:ANIK) institutional sentiment increased to 1.32 in Q2 2018. Its up 0.08, from 1.24 in 2018Q1. The ratio is better, as 78 investment professionals opened new or increased stock positions, while 59 decreased and sold stock positions in Anika Therapeutics Inc. The investment professionals in our partner’s database now hold: 13.16 million shares, up from 12.25 million shares in 2018Q1. Also, the number of investment professionals holding Anika Therapeutics Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 16 Reduced: 43 Increased: 49 New Position: 29.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $454.43 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 25.1 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

The stock decreased 2.05% or $0.67 during the last trading session, reaching $31.98. About 82,621 shares traded. Anika Therapeutics, Inc. (NASDAQ:ANIK) has declined 25.99% since December 6, 2017 and is downtrending. It has underperformed by 41.61% the S&P500.

Analysts await Anika Therapeutics, Inc. (NASDAQ:ANIK) to report earnings on February, 20. They expect $0.35 earnings per share, down 7.89 % or $0.03 from last year’s $0.38 per share. ANIK’s profit will be $4.97 million for 22.84 P/E if the $0.35 EPS becomes a reality. After $0.53 actual earnings per share reported by Anika Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -33.96 % negative EPS growth.

Capital Management Corp Va holds 1.11% of its portfolio in Anika Therapeutics, Inc. for 128,737 shares. Thomson Horstmann & Bryant Inc owns 264,751 shares or 1.03% of their US portfolio. Moreover, Ami Asset Management Corp has 0.79% invested in the company for 344,668 shares. The Massachusetts-based Portolan Capital Management Llc has invested 0.53% in the stock. Piermont Capital Management Inc., a Missouri-based fund reported 45,124 shares.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Ratings analysis reveals 50% of Anika Therapeutics Inc’s analysts are positive. Out of 2 Wall Street analysts rating Anika Therapeutics Inc, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. ANIK was included in 2 notes of analysts from June 20, 2018. The stock of Anika Therapeutics, Inc. (NASDAQ:ANIK) earned “Outperform” rating by Barrington Research on Friday, July 27. First Analysis downgraded the stock to “Hold” rating in Wednesday, June 20 report.

More notable recent Anika Therapeutics, Inc. (NASDAQ:ANIK) news were published by: which released: “Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” on July 26, 2018, also with their article: “Anika Therapeutics Inc. 2018 Q2 – Results – Earnings Call Slides – Seeking Alpha” published on July 26, 2018, published: “Anika Therapeutics’ CINGAL flunks late-stage knee osteoarthritis study; shares down 21% after hours – Seeking Alpha” on June 19, 2018. More interesting news about Anika Therapeutics, Inc. (NASDAQ:ANIK) were released by: and their article: “What’s in Store for Anika Therapeutics (ANIK) in Q3 Earnings? –” published on October 22, 2018 as well as‘s news article titled: “Anika Therapeutics: Strong Earnings Coupled With Improving Prospects – Seeking Alpha” with publication date: August 02, 2018.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.